Misonix Incorporated Release: New Data Reports Reduction in Blood Loss With Misonix SonicOne® O.R. In Burn Patients

FARMINGDALE, N.Y., Nov. 10, 2014 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announced that new data on SonicOne O.R. was presented at the American Burn Association's ("ABA") 2014 Western Regional Burn Conference in Las Vegas, NV, held November 6-9, 2014. The ABA and its more than 3,500 members promote and support burn-related research, education, care, rehabilitation and prevention.

The SonicOne O.R. is an innovative surgical device that allows surgeons to address the challenges chronic wounds present to them, the patient, and the health-care system. SonicOne O.R. establishes a new standard in surgical wound bed preparation, an essential first step in the wound healing process. Use of the SonicOne O.R. system provides controlled tissue removal, decreased healing times, reduced bleeding and a reduction of biofilm.

Abraham Houng, MD, Associate Program Director for the Division of Burn Surgery at Saint Barnabas Medical Center in Livingston, New Jersey (the 5^th largest burn center in the United States) presented an abstract entitled, Using Ultrasonic Technology for Tangential Burn Excision. The study concluded that "Surgical Debridement System (Misonix SonicOne O.R.) is safe and effective for use in tangential excision of third degree burn wounds." Dr. Houng further commented, "The calculated blood loss using SonicOne O.R. is significantly less than published blood loss using standard excision technique and this represents a very important advancement in the treatment of this very sick patient population."

"These study results provide further clinical evidence to support the safety and effectiveness of SonicOne O.R. ultrasonic technology in the treatment of burn wounds.  We remain enthusiastic as we continue to see more and more facilities electing to bring SonicOne O.R. into their operating rooms.  This new data presented at the ABA meeting further validates the clinical benefits of our unique technology," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.